Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough cell-free platform

Co-founder of Invizyne and UCLA Professor Emeritus James Bowie, states, “We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether. I was lucky to have a team with enough talent and grit to actually make it work.”

Invizyne's CEO, Michael Heltzen, adds, "Today is an amazing day. That's one of those typical overnight successes that takes a decade to prepare for. We are from a perspective of IPOing, an early stage IPO. It means, this is in no way a celebration to exit and like 'it's over'. It's the exact the opposite: Today, we start the real journey on introducing the world to cell-free biomanufacturing!"

See the full interview below. Press releases available here:

https://www.invizyne.com/nasdaq-ipo

Invizyne is trading on Nasdaq under the ticker symbol "IZTC".

#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech #nasdaq #IPO